Peptide Heavy Metals Testing: What USP <232>/<233> Checks and Why It Matters for Injectables

Heavy metals testing on a peptide answers two opposite questions. On most compounds it asks whether a metal is present that should not be. On GHK-Cu and AHK-Cu it asks whether the metal that is supposed to be there actually is.

Elemental analysis is the one assay that answers both, and we have not seen it offered by any vendor or laboratory serving this market. Both copper peptides sit in the skin and anti-aging peptides category; the reason a purity certificate cannot substitute is set out in what HPLC testing measures.

What does heavy metals testing measure on a peptide?

Elemental analysis measures the metal content of a sample directly, which is something no routine peptide assay does. HPLC separates by hydrophobicity and reports peak area, detecting no metals whatsoever. Mass spectrometry reports a mass, which shifts when a metal is bound but says nothing about metal content. That single capability is what makes elemental analysis the answer to both the contamination question and the is-the-copper-there question, and it is why neither is settled by a certificate showing 99% purity.

The two framings are worth separating before going further, because they pull in opposite directions. Contamination treats a metal as something to be excluded, and the desired result is as close to nothing as the method can report. Composition treats a metal as the declared active component, and the desired result is a specific quantity at a specific stoichiometry. The same instrument answers both. Only one of the two has any presence in this market's paperwork, and it is not the one most readers expect.

What does this record actually show about heavy-metal contamination?

Very little, and saying so is more useful than implying otherwise. We found no heavy-metal contamination results anywhere in this fact base — no reported lead, cadmium, arsenic or mercury figures on any compound, and no elemental analysis offered by any vendor or laboratory serving this market. Finding none is not the same as none existing. It means the question has not been asked in public here, so there is no evidence of a contamination problem and equally no evidence against one.

That is a deliberately flat conclusion. The temptation on a page about heavy metals is to imply a hazard the data does not support, and the honest position is that the contamination axis in this market is unmeasured rather than clean or dirty. Where this corpus does carry documented failures, they are elsewhere: fill quantity, identity substitution, salt-form ambiguity and, on injectables, pyrogens — the last of these with a Class I recall of an NAD+ injection classified on 21 October 2025, covered in endotoxin testing and the LAL assay.

Which peptides make the metal the point rather than the impurity?

Two, and they are structurally almost the same molecule. GHK-Cu and AHK-Cu are copper complexes: the metal is the declared active component rather than a contaminant, and a vial without it is not a purer product but a different one. GHK-Cu is a 1:1 copper complex of the tripeptide glycyl-histidyl-lysine; AHK-Cu is the same arrangement with alanine replacing glycine at position 1, a difference of one methylene group. For both, the question "is there metal in this?" has the answer "there had better be."

Both percentages are our own calculation from the verified molecular weights and copper's atomic weight of 63.546, not registry values, and they are the figures every dose calculation below rests on. The compound science sits at GHK-Cu and AHK-Cu.

How much elemental copper does a GHK-Cu dose deliver?

GHK-Cu is 15.7–15.8% elemental copper by mass, so a 10 mg dose carries about 1,577 µg of copper — roughly 175% of the 900 µg adult RDA — and a 20 mg dose about 3,154 µg. That is our calculation from the verified molecular weights and copper's atomic weight of 63.546. No human pharmacokinetic data exists for this compound by any route, so nothing in the literature describes how a parenteral copper load of that size is handled once it is in.

The NIH Office of Dietary Supplements sets the adult copper RDA at 900 µg/day and the Tolerable Upper Intake Level at 10,000 µg/day. Those are the two reference points the table is scaled against, and the second column is the one that matters practically: at typical doses, a person injecting GHK-Cu is administering multiples of an entire day's dietary copper requirement in a single dose. Per-injection volume arithmetic is in the GHK-Cu calculator and the reconstitution calculator, and the protocol context in the GHK-Cu dosage guide.

Why is the oral copper upper limit the wrong comparison?

Because the 10,000 µg/day Tolerable Upper Intake Level is an oral limit, and oral copper absorption is actively regulated by the intestine while injection bypasses that gate entirely. A 10 mg GHK-Cu dose carries about 16% of the oral UL, so the arithmetic does not show that injection exceeds it. The obvious framing is wrong and worth resisting. What matters is the exit route, and as the parenteral nutrition literature states, copper levels are primarily regulated by biliary excretion.

The source for the exit route is Corkins, Martin and Szeszycki (JPEN 2013), who state that "copper levels are primarily regulated by biliary excretion." Injection does not bypass biliary clearance, but it also does not benefit from absorptive gating. In paediatric parenteral nutrition, standard copper dosing is 20 µg/kg/day, and Burjonrappa and Miller (Journal of Pediatric Surgery, 2012) note that "copper and manganese need to be withheld if the neonate develops PN-associated liver disease." Clinicians who give copper parenterally watch the liver.

So the defensible statement is this: a 10–20 mg GHK-Cu injection delivers 1.6–3.2 mg of elemental copper parenterally — multiples of the entire daily dietary requirement — into a system whose only meaningful excretion route is bile, in a person whose hepatic status is unknown and unmonitored, with zero human pharmacokinetic data for this compound. That is a real, quantified concern. It is not a claim that GHK-Cu causes copper toxicity, and no study shows that.

Who is at particular risk from injected copper?

People who cannot clear it. NIH summarises the general risk as "chronic exposure to high levels of copper can result in liver damage and gastrointestinal symptoms," and people with Wilson's disease — an autosomal recessive defect in copper clearance — are at particular risk, able to develop "neurologic and liver damage that can result in cirrhosis," acute hepatitis, haemolytic crisis and liver failure. Many people carrying a relevant mutation do not know it, which is what makes the risk hard to manage outside a clinical setting.

Wilson's disease is usually identified because someone became symptomatic or because a relative was diagnosed, and no vendor screens for it. Seek genotype or ceruloplasmin testing before any copper-containing injectable if there is liver disease, unexplained neurological symptoms or a family history of either. Reduce or stop entirely if liver function markers move. FDA's own position on the injectable route is narrower than a safety clearance and stronger than most summaries suggest, since its retained assessment reads: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations."

Why is AHK-Cu's label arithmetic worse than GHK-Cu's?

Because its published mass and its published CAS number frequently describe different substances. AHK-Cu's monohydrochloride is 452.39 at CAS 682809-81-0, while the uncharged complex is approximately 415.94 — so a vendor quoting "AHK-Cu, MW 415.9, CAS 682809-81-0" has mismatched the salt form to the mass, a 36 Da error of about 8% that runs straight into a dose calculation. On top of that sits the same copper-versus-copper-free problem as GHK-Cu, at a gap of roughly 98 Da.

AHK-Cu is roughly 14% elemental copper by mass in the hydrochloride form, again our calculation from the verified molecular weights. Milligram doses therefore deliver hundreds of micrograms of copper, a substantial fraction of the 900 µg/day adult RDA, administered parenterally in someone whose hepatic copper handling has not been assessed. The same considerations apply as for GHK-Cu with less data behind them, since no human pharmacokinetic data exists for this compound at all and the entire market rests on one 2007 in vitro paper. Salt-form arithmetic in general is covered in TFA versus acetate versus amidate peptide salt forms.

Can a purity certificate tell you whether the copper is there?

No, and this is the sharpest analytical failure in the cluster. HPLC separates by hydrophobicity and detects no metals, so a vial of pure copper-free GHK returns a beautiful purity figure. The copper is roughly 18% of the molecule and about 62.5 daltons, a difference that is enormous by peptide-identity standards and trivially visible to mass spectrometry, and completely invisible to the assay almost every certificate in this market actually reports.

The confusion is not confined to vendors. PubChem indexes the copper-free tripeptide, CID 73587, under the synonyms "GHK-Cu," "Copper Peptide," "Copper(II)ghk," "Copper glycyl-histidyl-lysine," "Prezatide" and "Tripeptide-1" — six names for a copper complex, attached to a molecule containing no copper. If the world's largest chemical database conflates the two, a vendor label can. Our own compound page independently flags the consequence, noting that "some vendors sell free GHK labeled as GHK-Cu (mislabeling) or use suboptimal copper-to-peptide ratios," and the document-level version of the pattern is catalogued in red flags in peptide certificates of analysis.

Which test answers the metal question, and why does nobody offer it?

Elemental analysis, and the honest answer to the second half is that nobody in this market sells it. Elemental analysis measures copper content directly at 1:1 stoichiometry, mass spectrometry separates 340.38 from ~403 instantly, and HPLC purity does neither — and of those three, only HPLC is routinely supplied. We have not seen elemental analysis offered by any vendor or laboratory serving this market, on either copper peptide or on any compound where contamination would be the question.

Read the availability column downwards. The test that answers the question is unavailable, the test that partly answers it is available and seldom used, and the test that cannot answer it at all is the one printed on nearly every certificate. That ordering is the practical situation a buyer of either copper peptide is in, and mass spectrometry is the workable substitute — the reasoning is in mass spectrometry for peptides.

What can elemental analysis not tell you?

Almost everything else about the vial. A copper figure establishes how much metal is present and nothing about whether the organic part is the right peptide, how much peptide is there, whether the material is homogeneous, whether it is sterile or whether it carries pyrogens. On a compound where the metal is the point, that still leaves the identity of the tripeptide unverified; on a compound where the metal would be a contaminant, it leaves every question the rest of the certificate exists to answer.

The last row needs no instrument at all, which is worth noticing on a page about an assay nobody offers. Two of the most useful checks available on these compounds are free: read the mass against the CAS number, and read the mass against the copper complex rather than the free peptide.

Which heavy-metals claims survive scrutiny?

Four hold, three fail and one is unmeasured. The copper arithmetic holds, the biliary excretion route holds, the Wilson's disease risk holds and the invisibility of copper to HPLC holds. What fails is the inference that a purity certificate speaks to metal content, the use of the oral upper limit as a parenteral benchmark, and the assumption that a high purity figure on a copper peptide is reassuring. The contamination question is not false — it is simply not measured anywhere in this record.

What does platform data show for the two copper peptides?

It shows the deepest purity dataset on the platform answering the wrong question. The Purity Index records GHK-Cu at 99.66% average across 736 independent HPLC tests (verified May 2026) across 230 verified vendors, individual results running 99.31% to 99.94%, most recent test August 2026. None of those 736 tests measures copper. AHK-Cu records 97.38% across 25 tests from five named laboratories — Vanguard, ILS, Kovera, Janoshik and Freedom Diagnostics — across 221 verified vendors (verified May 2026).

The AHK-Cu figure is worth reading as an illustration of thin coverage rather than of poor quality. One vendor's June 2026 test returned 50.63% purity with a 10.6% quantity shortfall, and the remaining tests cluster above 99%; on a 25-test dataset that single outlier drags the category average down by nearly two percentage points, where on GHK-Cu's 736 tests an outlier stays visible as an outlier. Read individual vendor results rather than category averages whenever the test count is that low.

GHK-Cu price data shows 59 shops in stock, median $0.70/mg, lowest $0.12/mg on a 100 mg vial (verified 8 August 2026), and AHK-Cu price data shows 9 shops in stock, median $0.70/mg, lowest $0.38/mg on a 100 mg vial at $38.00 (verified 9 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Peptigrity tracks 530 shops, 11,852 independent lab tests, 118 peptides and 1,283 community reviews (verified August 2026), weighting community reviews and independently verified purity equally at 50% each — a weighting that, on these two compounds, contains no term for the component the buyer is paying for. Listings sit on the GHK-Cu compound page and the AHK-Cu compound page, with individual certificates in the independent lab tests database.

The trial that would settle what is actually in a copper peptide vial

No study has taken vials sold as GHK-Cu or AHK-Cu, run elemental analysis on every one, and reported how many contained copper at the declared stoichiometry. That study needs no new method — it is a purchase, an assay and a table — and its absence is the reason this page can quantify what a dose delivers if the copper is there while saying nothing about how often it is. The contamination arm of the same study would answer the other half.

What to ask for before the money moves

Five requests, and on a copper peptide the order is not the usual one. Ask for a mass spectrometry result matching the copper complex rather than the free peptide, the stated salt form, the CAS number checked against the stated mass, a net content figure and an LAL endotoxin result — and if elemental analysis is genuinely available, ask for that first. A purity percentage is the least informative document on these two compounds, which is the reverse of how it works everywhere else.

Before any of that, there is a medical check that is not about the vial. If there is liver disease, unexplained neurological symptoms or a family history of either, copper status and Wilson's disease screening belong with a clinician and ahead of any purchasing question.

Frequently Asked Questions

Do peptide vendors test for heavy metals?

We have not seen elemental analysis offered by any vendor or laboratory serving this market, on either the contamination question or on the copper peptides where the metal is the declared active component. Certificates in this market report HPLC purity, sometimes mass spectrometry, occasionally net content, and very rarely endotoxin. Metals are not on the list.

How much copper is in a GHK-Cu injection?

GHK-Cu is about 15.8% elemental copper by mass, our calculation from the verified molecular weights and copper's atomic weight of 63.546. A 10 mg dose carries roughly 1,577 µg, about 175% of the 900 µg adult daily requirement, and a 20 mg dose about 3,154 µg. No human pharmacokinetic data exists for the compound.

Is injected copper dangerous?

No study shows that GHK-Cu causes copper toxicity, and the arithmetic does not exceed the oral upper limit at typical doses. The quantified concern is different: milligram quantities of copper delivered parenterally, bypassing intestinal absorptive regulation, into a system whose only meaningful exit route is bile, in someone whose liver status is unmonitored.

Who should avoid copper peptides?

People with Wilson's disease, an autosomal recessive defect in copper clearance, are at particular risk and can develop neurologic and liver damage that can result in cirrhosis, acute hepatitis, haemolytic crisis and liver failure. Many carriers do not know they have it. Anyone with liver disease, unexplained neurological symptoms or a family history of either should get copper status checked first.

Can HPLC purity confirm that a copper peptide contains copper?

No. HPLC separates by hydrophobicity and detects no metals, so a vial of pure copper-free GHK returns an excellent purity number. The copper is about 62.5 daltons and roughly 18% of the molecule, which mass spectrometry resolves instantly and purity testing cannot see at all. PubChem itself files the copper-free peptide under GHK-Cu synonyms.

Are research peptides contaminated with heavy metals?

Nobody has published a measurement, so there is no evidence of a problem and no evidence against one. This record carries no lead, cadmium, arsenic or mercury results on any compound. Finding none is not the same as none existing; it means the contamination question in this market is unmeasured rather than answered.

Browse the skin and anti-aging peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the GHK-Cu calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.